XM does not provide services to residents of the United States of America.

Grail says about 400 patients incorrectly informed they may have cancer



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Grail says about 400 patients incorrectly informed they may have cancer</title></head><body>

Updates paragraph 1, adds details from the company statement in paragraph 4

June 2 (Reuters) -Cancer test maker Grail Inc GRAL.O said on Friday that its telemedicine vendor erroneously sent letters to about 400 patients suggesting they may have developed cancer.

Grail's flagship cancer detection blood test Galleri is designed to detect more than 50 types of cancer before symptoms appear.

The company, owned by Illumina Inc ILMN.O, said the letters were mistakenly sent by PWNHealth due to a software issue and that it "was in no way related to or caused by an incorrect Galleri test result".

Grail said it had reached out to the patients immediately after the issue, adding that no patient health information has been disclosed or breached due to this.

The software issue being faced by PWNHealth has now been resolved, it said.

Illumina is currently appealing regulatory orders in the U.S. and EU, which are asking the gene sequencing company to divest Grail after it jumped regulators to close its acquisition of the cancer test maker.




Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.